Ibyerekeye-kanseri / kuvura / ivuriro-ibigeragezo / indwara / merkel-selile / kuvura

Kuvura Igeragezwa rya Kanseri ya Merkel

Igeragezwa rya Clinical ni ubushakashatsi bwubushakashatsi burimo abantu. Ibizamini byamavuriro kururu rutonde ni ibya kanseri ya Merkel. Ibigeragezo byose kurutonde bishyigikiwe na NCI.

Amakuru yibanze ya NCI kubyerekeye ibizamini byamavuriro asobanura ubwoko nicyiciro cyibigeragezo nuburyo bikorwa. Igeragezwa rya Clinical rireba uburyo bushya bwo kwirinda, gutahura, cyangwa kuvura indwara. Urashobora gushaka gutekereza kubijyanye no kwitabira ikizamini cyamavuriro. Vugana na muganga wawe kugirango agufashe guhitamo niba umwe akubereye.

Ikigeragezo 1-25 kuri 32 1 2 Ibikurikira>

Pembrolizumab Ugereranije nubuziranenge bwo Kwita ku Kuvura abarwayi bafite Icyiciro Cyuzuye Cyuzuye I-III Kanseri y'akagari ka Merkel

Iki cyiciro cya III cyigeragezo cyiga uburyo pembrolizumab ikora neza ugereranije nubuziranenge bwo kwita kubuvuzi mu kuvura abarwayi ba kanseri yo mu cyiciro cya I-III Merkel yakuweho burundu no kubagwa (resected). Immunotherapy hamwe na antibodiyite za monoclonal, nka pembrolizumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zikura no gukwirakwira. Aho uherereye: 286

Pembrolizumab hamwe na Stereotactique Imirasire yumubiri mu kuvura abarwayi bafite kanseri yo mu bwoko bwa Merkel yateye imbere cyangwa Metastatike

Igeragezwa ryicyiciro cya kabiri cyiga uburyo pembrolizumab ifite cyangwa idafite imiti ivura imirasire yumubiri itagira imbaraga ikora mukuvura abarwayi ba kanseri ya selile ya Merkel yakwirakwiriye ahandi mu mubiri. Immunotherapy hamwe na antibodiyite za monoclonal, nka pembrolizumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zikura no gukwirakwira. Imiti ivura imirasire ya stereotactique ikoresha ibikoresho byihariye kugirango ishyire umurwayi kandi itange imirasire yibibyimba neza. Ubu buryo burashobora kwica selile yibibyimba hamwe na dosiye nkeya mugihe gito kandi bigatera kwangirika kwinyama zisanzwe. Gutanga pembrolizumab hamwe nubuvuzi bwimirasire yumubiri bishobora gukora neza mukuvura abarwayi ba kanseri ya selile ya Merkel.

Aho uherereye: 246

Iperereza ryakozwe na Immuno-therapy Inyigo yo gukora iperereza ku mutekano n’ingirakamaro bya Nivolumab, hamwe nubuvuzi bwa Nivolumab mu kuvura indwara ziterwa na virusi.

Intego yubu bushakashatsi yo gukora iperereza ku mutekano n’ingirakamaro bya nivolumab, hamwe n’ubuvuzi bwa nivolumab, kuvura abarwayi bafite ibibyimba biterwa na virusi. Virusi zimwe zizwiho kugira uruhare mukubyimba no gukura. Ubu bushakashatsi buzasesengura ingaruka z’imiti y’ubushakashatsi, ku barwayi bafite ibibyimba bikurikira: - Kanseri yo mu muyoboro w’amaraso-Ntibikiri kwandikisha ubu bwoko bw’ibibyimba - Kanseri y'inkondo y'umura - Epstein Barr Virus (EBV) kanseri nziza yo mu gifu-Ntibikiyandikisha ibi ubwoko bw'ikibyimba - Kanseri y'akagari ka Merkel - Kanseri y'imboro-Ntibikiri kwiyandikisha muri ubu bwoko bw'ikibyimba - Kanseri yo mu nda ibyara na vulvar-Ntibikiri kwiyandikisha muri ubu bwoko bw'ikibyimba - Kanseri ya Nasopharyngeal - Ntukiyandikisha ubu bwoko bw'ikibyimba - Kanseri yo mu mutwe no mu ijosi - Ntabwo ukiyandikisha ubu bwoko bw'ikibyimba

Aho uherereye: ahantu 10

Ubu bushakashatsi busuzuma KRT-232, Inzitizi yo mu kanwa Ntoya ya Molecule Inhibitor ya MDM2, yo kuvura abarwayi bafite (p53WT) Mercel Cell Carcinoma Yananiwe Kurwanya PD-1 / PD-L1 Immunotherapy

Ubu bushakashatsi busuzuma KRT-232, igitabo gishya cya molekile ntoya yo mu kanwa ya MDM2, kugira ngo ivure abarwayi bafite kanseri ya Merkel Cell Carcinoma (MCC) bananiwe kwivuza nibura imwe irwanya PD-1 cyangwa irwanya PD-L1. Kubuza MDM2 nuburyo bushya bwibikorwa muri MCC. Ubu bushakashatsi ni Icyiciro cya 2, Gufungura-Ikirango, Kwiga ukuboko kumwe kwa KRT-232 ku barwayi bafite p53 Ubwoko bw'inyamanswa (p53WT) Merkel Cell Carcinoma

Aho uherereye: ahantu 11

Adjuvant Avelumab muri Kanseri ya Merkel

Igeragezwa ryicyiciro cya III ryiga uburyo avelumab ikora neza mukuvura abarwayi ba kanseri ya selile ya Merkel yakwirakwiriye mu mitsi kandi bakaba barabazwe cyangwa badafite imiti ivura imirase. Antibodiyite za Monoclonal, nka avelumab, zirashobora gukangura ubudahangarwa bw'umubiri kandi bikabangamira ubushobozi bw'uturemangingo tw'ibibyimba gukura no gukwirakwira.

Aho uherereye: ahantu 10

QUILT-3.055: Inyigo ya ALT-803 ifatanije na PD-1 / PD-L1 Inhibitor ya Inhibitor mu barwayi bafite Kanseri Yateye imbere

Iki nicyiciro cya IIb, ukuboko kumwe, multicohort, gufungura-label multicenter ubushakashatsi bwakozwe na ALT-803 bufatanije na FDA yemewe na PD-1 / PD-L1 inhibitori kubarwayi bafite kanseri yateye imbere bateye imbere nyuma yo kubisubiza bwa mbere kuvura hamwe na PD-1 / PD-L1 igenzura rya inhibitori. Abarwayi bose bazahabwa imiti ivura PD-1 / PD-L1 igenzura hiyongereyeho ALT-803 kugeza kuri 16. Buri cyiciro ni ibyumweru bitandatu. Abarwayi bose bazahabwa ALT-803 rimwe mubyumweru 3. Abarwayi bazahabwa kandi inhibitori ya bariyeri bakiriye mugihe cyo kuvura kwabo. Isuzuma rya radiologique rizabaho nyuma ya buri cyiciro cyo kuvura. Umuti uzakomeza kugeza kumyaka 2, cyangwa kugeza igihe umurwayi yiboneye yemeje indwara igenda itera imbere cyangwa uburozi butemewe, akuraho uruhushya, cyangwa niba Umushakashatsi yumva bitakiri inyungu zumurwayi gukomeza kwivuza. Abarwayi bazakurikiranwa niterambere ryindwara, nyuma yubuvuzi, no kubaho mugihe cyamezi 24 ashize ubuyobozi bwa mbere bwibi biyobyabwenge.

Aho uherereye: ahantu 9

Ubushakashatsi bwa NKTR-262 bufatanije na NKTR-214 hamwe na NKTR-214 Plus Nivolumab mu barwayi bafite Indwara mbi cyangwa Metastatike Solid Tumor Malignancies

Abarwayi bazahabwa intra-tumorale (IT) NKTR-262 mugihe cyibyumweru 3 byo kuvura. Mugice cya 1 dose escalation igice cyiburanisha, NKTR-262 izahuzwa nubuyobozi bwa sisitemu ya bempegaldesleukin. Nyuma yo kumenya icyiciro cya 2 gisabwa (RP2D) cya NKTR-262, abarwayi bari hagati ya 6 na 12 barashobora kwiyandikisha kuri RP2D kugirango barusheho kuranga imiterere yumutekano no kwihanganira guhuza NKTR 262 hiyongereyeho bempegaldesleukin (kabiri) cyangwa NKTR 262 wongeyeho bempegaldesleukin ifatanije na nivolumab (inyabutatu) muri Cohorts A na B, kimwe. Mugice cya 2 icyiciro cyo kwagura igice, abarwayi bazavurwa inshuro ebyiri cyangwa eshatu mugice cyisubiramo / cyangiritse hamwe nimirongo yambere yubuvuzi.

Aho uherereye: ahantu 14

Ubushakashatsi bwa INCMGA00012 muri Metastatike Merkel Cell Carcinoma (POD1UM-201)

Intego yubu bushakashatsi ni ugusuzuma ibikorwa byubuvuzi n’umutekano bya INCMGA00012 mubitabiriye hamwe na kanseri ya selile ya Merkel yateye imbere (MCC).

Aho uherereye: ahantu 8

Ikaramu-221 muri reseptor ya Somatostatin 2 Kugaragaza Kanseri Yateye imbere Harimo Neuroendocrine na Kanseri Ntoya y'ibihaha

Porotokole PEN-221-001 ni label ifunguye, multicenter Icyiciro cya 1 / 2a isuzuma PEN-221 kubarwayi barwaye SSTR2 igaragaza gastroenteropancreatic (GEP) cyangwa ibihaha cyangwa thymus cyangwa ibindi bibyimba bya neuroendocrine cyangwa kanseri ntoya y'ibihaha cyangwa kanseri nini ya selile neuroendocrine. y'ibihaha.

Aho uherereye: ahantu 7

Icyiciro 1/2 Kwiga Mubukingo bwa Situ Hamwe na Tremelimumab na IV Durvalumab Yongeyeho PolyICLC mubintu bifite Kanseri Yateye imbere, Yapimwe, Biopsy-ishobora kuboneka

Ubu ni label ifunguye, multicenter Icyiciro 1/2 ubushakashatsi bwa antibody ya CTLA-4, tremelimumab, hamwe na antibody ya PD-L1, durvalumab (MEDI4736), ifatanije na microc ibidukikije yibibyimba (TME) modulator polyICLC, agroniste wa TLR3, mu masomo afite kanseri yateye imbere, ipimwa, biopsy-ishobora kuboneka.

Aho uherereye: ahantu 6

Intratumoral AST-008 Yahujwe na Pembrolizumab mu barwayi bafite ibibyimba bikomeye

Iki nicyiciro cya 1b / 2, fungura-label, igeragezwa ryinshi rigamije gusuzuma umutekano, kwihanganira, imiti ya farumasi, imiti ya farumasi ningaruka zambere zo gutera inshinge AST-008 yonyine kandi ifatanije na pembrolizumab yimitsi itwara abarwayi bafite ibibyimba bikomeye. Icyiciro cya 1b cyiki kigeragezo ni 3 + 3 igipimo cyo kuzamura igipimo cyerekana urugero rwinshi cyangwa intera ndende ya AST-008 yatanzwe hamwe nigipimo cyagenwe cya pembrolizumab. Icyiciro cya 2 ni itsinda ryagutse kugirango barusheho gusuzuma AST-008 yatanzwe ifatanije na pembrolizumab mu baturage runaka kugira ngo batange igereranyo kibanza cy’ingaruka ku barwayi bakiriye mbere kandi batitabira antibody anti-PD-1 cyangwa anti-PD-L1 ubuvuzi.

Aho uherereye: ahantu 7

Ikigeragezo cyo Gutera Intratumoral TTI-621 mubintu bifite ibibyimba byongeye kandi byangirika hamwe na Mycose Fungoides

Ubu ni uburyo bwinshi, bufungura-label, icyiciro cya 1 ubushakashatsi bwakozwe mugupima inshinge za TTI-621 mumasomo yasubiwemo kandi yangiritse ku buryo bworoshye ibibyimba bikomeye cyangwa mycose fungoide. Ubushakashatsi buzakorwa mubice bibiri bitandukanye. Igice cya 1 nicyiciro cya Dose Escalation naho igice cya 2 nicyiciro cyo Kwagura. Intego yubu bushakashatsi ni ukuranga umwirondoro wumutekano wa TTI-621 no kumenya igipimo cyiza nogutanga gahunda ya TTI-621. Byongeye kandi, ibikorwa by’umutekano n’ibikorwa bya TTI-621 bizasuzumwa bifatanije n’ibindi bikoresho birwanya kanseri cyangwa imirasire.

Aho uherereye: ahantu 5

Kwiga RP1 Monotherapy na RP1 muguhuza na Nivolumab

RPL-001-16 ni Icyiciro 1/2, ikirango gifunguye, dose escalation hamwe no kwagura ivuriro rya RP1 ryonyine kandi rifatanije na nivolumab mubantu bakuze bafite ibibyimba byateye imbere kandi / cyangwa byanze bikunze, kugirango bamenye urugero rwinshi rwihanganirwa (MTD) kandi twasabye icyiciro cya 2 dose (RP2D), kimwe no gusuzuma imikorere ibanza.

Aho uherereye: ahantu 6

Talimogene Laherparepvec hamwe na Hypofractionated Imirasire ivura abarwayi mu kuvura abarwayi bafite Melanoma ya Metastatike, Carcinoma ya Merkel, cyangwa Ibibyimba bikomeye.

Iki cyiciro cya kabiri cyateganijwe cyiga ku ngaruka ziterwa na talimogene laherparepvec no kureba uburyo ikorana cyangwa idafite imiti ivura imishwarara ya hypofraction mu kuvura abarwayi bafite melanoma y'uruhu, kanseri ya Merkel, cyangwa ibindi bibyimba bikomeye byakwirakwiriye ahantu hadakwiriye gukurwaho kubagwa . Ibiyobyabwenge bikoreshwa mu gukingira indwara, nka talimogene laherparepvec, birashobora gutuma umubiri w’umubiri urwanya selile. Hypofractionated radiation therapy itanga urugero rwinshi rwo kuvura imirasire mugihe gito kandi irashobora kwica selile nyinshi kandi ikagira ingaruka nke. Kugeza ubu ntiharamenyekana niba gutanga talimogene laherparepvec hamwe n’imiti ivura imishwarara ya hypofraction itazakora neza mu kuvura abarwayi bafite melanoma ya kanseri, kanseri ya Merkel, cyangwa ibibyimba bikomeye.

Aho uherereye: ahantu 3

FT500 nka Monotherapy no muguhuza hamwe na Immune Kugenzura Inhibitori mubintu hamwe nibibyimba bikomeye

FT500 ni ibicuruzwa bitemewe, bikomoka kuri iPSC biva mu ngirabuzimafatizo ya NK bishobora gukuraho ubudahangarwa bw'umubiri ndetse no guhuza n'imihindagurikire y'ikirere, kandi bifite ubushobozi bwo gutsinda uburyo bwinshi bwo kurwanya indwara zanduza indwara (ICI). Amakuru yibanze atanga ibimenyetso bifatika bishyigikira iperereza ryamavuriro ya FT500 nka monotherapy kandi ifatanije na ICI mubice bifite ibibyimba bikomeye.

Aho uherereye: ahantu 3

Tacrolimus, Nivolumab, na Ipilimumab mu kuvura abahawe impyiko hamwe na kanseri zatoranijwe zidashobora gukemurwa cyangwa Metastatike

Iki cyiciro cya I ikigeragezo cyiga uburyo tacrolimus, nivolumab, na ipilimumab ikora neza mukuvura abahawe impyiko na kanseri idashobora gukurwaho no kubagwa (idashobora gukemurwa) cyangwa yakwirakwiriye ahandi mu mubiri (metastatike). Tacrolimus irashobora guhagarika imikurire ya selile yibibyimba ihagarika imisemburo ikenewe kugirango imikurire ikure. Immunotherapy hamwe na antibodiyite za monoclonal, nka nivolumab na ipilimumab, irashobora gufasha sisitemu yumubiri yumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira. Gutanga tacrolimus, nivolumab, na ipilimumab birashobora gukora neza mukuvura abahawe impyiko na kanseri ugereranije na chimiotherapie, kubaga, kuvura imirasire, cyangwa kuvura intego.

Aho uherereye: ahantu 2

Nivolumab na Ipilimumab hamwe na Stereotactique Imirasire yumubiri wa Stereotactique mu kuvura abarwayi bafite Kanseri Yisubiramo cyangwa Icyiciro cya IV Merkel

Igeragezwa ryicyiciro cya II ryiga uburyo nivolumab na ipilimumab hamwe cyangwa bidafite imiti ivura imirasire yumubiri ya stereotactique ikora mukuvura abarwayi ba kanseri ya selile ya Merkel yagarutse cyangwa ni icyiciro cya IV. Immunotherapy hamwe na antibodiyite za monoclonal, nka nivolumab na ipilimumab, irashobora gufasha sisitemu yumubiri yumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira. Imiti ivura imirasire ya stereotactique ikoresha ibikoresho byihariye kugirango ishyire umurwayi kandi itange imirasire yibibyimba neza. Ubu buryo burashobora kwica selile yibibyimba hamwe na dosiye nkeya mugihe gito kandi bigatera kwangirika kwinyama zisanzwe. Gutanga nivolumab na ipilimumab hamwe cyangwa bidafite imiti ivura imirasire ya stereotactique irashobora gukora neza mukuvura abarwayi ba kanseri ya selile ya Merkel.

Aho uherereye: ahantu 2

Pembrolizumab hamwe nubuvuzi bwimishwarara yo kuvura kanseri ya selile ya Merkel

Iki cyiciro cya II cyigeragezo cyiga ku ngaruka n'ingaruka pembrolizumab hamwe no kuvura imirasire ikora neza mu kuvura abarwayi barwaye kanseri ya selile ya Merkel yakwirakwiriye ahandi mu mubiri (metastatike). Immunotherapy hamwe na antibodiyite za monoclonal, nka pembrolizumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zikura no gukwirakwira. Imiti ivura imirasire ikoresha ingufu za x-ray kugirango yice selile yibibyimba no kugabanya ibibyimba. Gutanga pembrolizumab hamwe nubuvuzi bwimirasire birashobora kongera inyungu za pembrolizumab.

Aho uherereye: Ikigo cya Kanseri cya Stanford Palo Alto, Palo Alto, California

Ubushakashatsi bwa LY3434172, PD-1 na PD-L1 Antibody Bispecific Antibody, muri Kanseri Yambere

Intego nyamukuru yubu bushakashatsi ni ugusuzuma umutekano n’ubworoherane bw’imiti y’ubushakashatsi LY3434172, antibody ya PD-1 / PD-L1, abitabiriye bafite ibibyimba bikomeye.

Aho uherereye: MD Anderson Centre ya Kanseri, Houston, Texas

Ubuvuzi bwakagari (Tumor Infiltrating Lymphocytes) bwo kuvura Kanseri Yateye imbere, Metastatike, cyangwa Kanseri Yisubiramo

Iki cyiciro cya II cyikigereranyo cyiga uburyo kuvura ingirabuzimafatizo (hamwe na kanseri yinjira muri lymphocytes) bifasha mu kuvura kanseri ikomeye yakwirakwiriye mu ngingo zegeranye cyangwa hafi ya lymph node (yateye imbere mu karere), yakwirakwiriye mu bindi bice by'umubiri (metastatike), cyangwa ifite garuka (gusubiramo). Iki kigeragezo kirimo gufata selile bita lymphocytes (ubwoko bwamaraso yera) mubibyimba byabarwayi, kubikurira muri laboratoire ari byinshi, hanyuma bigasubiza umurwayi. Utugingo ngengabuzima twitwa tumor infiltrating lymphocytes naho ubuvuzi bwitwa selile selile. Gutanga imiti ya chimiotherapie mbere yuko selile zishobora guhagarika byigihe gito sisitemu yumubiri kugirango byongere amahirwe yuko selile zirwanya ibibyimba bizashobora kubaho mumubiri. Gutanga aldesleukin nyuma yubuyobozi bwakagari birashobora gufasha kanseri irwanya ibibyimba kubaho igihe kirekire.

Aho uherereye: Ishuri Rikuru rya Kanseri ya kaminuza ya Pittsburgh (UPCI), Pittsburgh, Pennsylvania

Ubuvuzi bwa Nivolumab na Imirasire cyangwa Ipilimumab nk'Ubuvuzi bwa Adjuvant mu kuvura abarwayi ba kanseri y'akagari ka Merkel

Iki cyiciro cya I ikigeragezo cyiga ku ngaruka n'ingaruka nivolumab ikora iyo itanzwe hamwe nubuvuzi bwimirasire cyangwa ipilimumab nkubuvuzi bujyanye no kuvura abarwayi ba kanseri ya selile ya Merkel. Immunotherapy hamwe na antibodiyite za monoclonal, nka nivolumab na ipilimumab, irashobora gufasha sisitemu yumubiri yumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira. Imiti ivura imirasire ikoresha ingufu za x-imirasire, imirasire ya gamma, neutron, proton cyangwa andi masoko kugirango yice selile yibibyimba no kugabanya ibibyimba. Gutanga nivolumab hamwe nubuvuzi bwimirasire cyangwa ipilimumab nyuma yo kubagwa bishobora kwica selile zose zisigaye.

Aho biherereye: Ikigo cya Leta ya Ohio muri Leta Yose ya Kanseri, Columbus, Ohio

Pembrolizumab (MK-3475) nkumurongo wambere wubuvuzi bwa kanseri ya Merkel Yambere (MK-3475-913)

Ubu ni ukuboko kumwe, gufungura-label, multicenter, efficacy, hamwe nubushakashatsi bwumutekano wa pembrolizumab mubantu bakuze n’abana bato hamwe na Mercel Cell Carcinoma yateye imbere mbere (MCC). Intego yibanze yikigeragezo ni ugusuzuma igipimo cyibisubizo bifatika, nkuko byasuzumwe n’isuzuma ryigenga ryigenga rihumye kuri buri gipimo cyo gusuzuma Isuzuma muri Solid Tumors verisiyo 1.1 (RECIST 1.1) yahinduwe kugirango ikurikirane ibikomere 10 byibasiwe kandi ntarengwa 5 byatewe. kuri buri rugingo, ukurikiza ubuyobozi bwa pembrolizumab.

Aho uherereye: Laura na Isaac Perlmutter Kanseri Ikigo cya NYU Langone, New York, New York

Ingirabuzimafatizo zahinduwe na Gene (FH-MCVA2TCR) mu kuvura abarwayi bafite kanseri y'uturemangingo ya Merkel cyangwa idashobora gukemurwa

Iki cyiciro cya I / II cyiga ku ngaruka ziterwa na selile immunite yahinduwe (FH-MCVA2TCR) no kureba uburyo bakora neza mukuvura abarwayi ba kanseri ya selile ya Merkel yakwirakwiriye mubindi bice byumubiri (metastatike) cyangwa idashobora gukurwaho no kubagwa (bidashoboka). Gushyira gene yakorewe muri laboratoire mu ngirabuzimafatizo z'umubiri birashobora kongera ubushobozi bw'umubiri bwo kurwanya kanseri ya Merkel.

Aho uherereye: Fred Hutch / Kaminuza ya Washington Kanseri ya Kanseri, Seattle, Washington

Umutekano no Kwihanganirana Kwiga INCAGN02390 muguhitamo Indwara mbi

Intego yubu bushakashatsi ni ukumenya umutekano, kwihanganira, hamwe nubushobozi bwambere bwa INCAGN02390 mubitabiriye amahugurwa hamwe nindwara mbi zateye imbere.

Aho uherereye: Ikigo cyubuvuzi cya kaminuza ya Hackensack, Hackensack, New Jersey

Abexinostat na Pembrolizumab mukuvura abarwayi hamwe na MSI-Yisumbuye Yateye imbere cyangwa Ibibyimba bikomeye bya Metastatike

Iki cyiciro cya I ikigeragezo cyiga urugero rwiza ningaruka za abexinostat nuburyo ikorana neza hamwe hamwe na pembrolizumab mukuvura abarwayi bafite microsatellite ihungabana (MSI) ibibyimba bikomeye byakwirakwiriye mubice bya hafi cyangwa lymph node (byateye imbere) mu mubiri (metastatike). Abexinostat irashobora guhagarika imikurire ya selile yibibyimba ihagarika imisemburo ikenewe kugirango imikurire ikure. Immunotherapy hamwe na antibodiyite za monoclonal, nka pembrolizumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zikura no gukwirakwira. Gutanga abexinostat na pembrolizumab birashobora gukora neza mukuvura abarwayi bafite ibibyimba bikomeye.

Aho uherereye: Ikigo cyubuvuzi cya UCSF-Umusozi wa Siyoni, San Francisco, California

1 2 Ibikurikira>